Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPRAISAL Trial: RESTEN-MP in Coronary Artery Lesions
NCT00248066Phase 2Completed
- Sponsor
- Sarepta Therapeutics
- Start
- Sep 2005
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avi-4126 in coronary restenosis, sponsored by Sarepta Therapeutics. Primary endpoints: Potential efficacy of RESTEN-MP given intravenously at 24 hours and Prevention of coronary late lumen loss at 6 months. Started Sep 2005; status: completed.
02
Drugs
avi-4126
03
Conditions
coronary restenosis
Beyond the preview
Go deeper on NCT00248066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00248066.